• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600613.SS
Share

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Stocks

CN¥ 5.11Last Updated 15.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 334.59M

CN¥ 5.11
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., through its various subsidiaries, functions as a pharmaceutical manufacturing holding and investment entity within China. The company's operations encompass the research, development, and production of a broad spectrum of medications. Its therapeutic focus includes pharmaceuticals for oncology, cardiovascular and cerebrovascular conditions, respiratory issues (such as colds and coughs), pediatric care, and antifungal treatments, alongside general health tonics. The firm's product portfolio features both prescription-only drugs and readily available over-the-counter (OTC) remedies. Established in Shanghai, China, in 1992, the company continues to operate from this location.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 11:45

HSBC has named Kaspi shares its top pick for July. Why does it expect them to rise by a third?

15.07.2026 11:26

PayPal Shares Surge: Fintech Giant Stripe Offers to Buy It — Reuters

15.07.2026 11:00

China's GDP growth has slowed to a three-year low. What can we expect from Beijing?

15.07.2026 10:25

Morning Roundup: IBM's Worst Day, Stripe Sets Its Sights on PayPal, and an OpenAI Gadget

15.07.2026 09:30

Goldman Sachs: The AI boom has reached the same scale as the dot-com boom, but is following a different trajectory

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026